Loading...
About ARTBIO
ARTBIO is a clinical-stage biotechnology company based in Norway, with additional offices in Cambridge, London, and Basel. Founded in 2021, it focuses on developing alpha radioligand therapies for cancer treatment. The company utilizes the alpha-emitting isotope lead-212 (Pb212) to create targeted therapies that aim to minimize damage to healthy tissues while effectively targeting tumor cells. The core innovation of ARTBIO is its AlphaDirect™ technology, which allows for reliable production and delivery of its therapies through a distributed manufacturing model. The company's lead clinical program, AB001, is designed to treat prostate cancer using these targeted alpha therapies. ARTBIO's approach combines a deep understanding of cancer biology with the necessary infrastructure for effective therapy design and distribution. ARTBIO was co-founded by experts in radiopharmaceuticals, Roy Larsen and Øyvind Bruland, and is led by CEO Emanuele Ostuni. The company operates with a business-to-consumer model, focusing on delivering innovative cancer therapies directly to patients and healthcare providers. It has secured significant funding, including a $23 million seed round from notable investors.
Open Positions at ARTBIO(5 jobs)
View all jobs →
Working at ARTBIO
ARTBIO is hiring for remote positions. As a research company, they offer opportunities for talented professionals to work from anywhere.
Check out the open positions above and apply directly. We aggregate job postings from ARTBIO's career page and LinkedIn to make it easier for you to find and apply.